Kaori Hino
YOU?
Author Swipe
View article: Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G)
Ramucirumab‐containing chemotherapy for patients with gastrointestinal neuroendocrine carcinoma refractory/intolerant to platinum‐based chemotherapy: A multicenter observational retrospective study (WJOG13420G) Open
No standard second‐line chemotherapy has been established for gastrointestinal neuroendocrine carcinoma (NEC). This study aimed to determine whether ramucirumab (RAM) is a treatment candidate in this setting. We retrospectively collected d…
View article: A case of ureteral orifice obstruction by bladder indwelling catheter
A case of ureteral orifice obstruction by bladder indwelling catheter Open
View article: Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort
Phase 1b/2 study of the liposomal formulation of eribulin (E7389-LF) in combination with nivolumab: Results from the phase 2 esophageal cancer cohort Open
Background Esophageal cancer is one of the most common types of cancer in Japan. Herein, we report the efficacy and safety of E7389-LF plus the immune checkpoint inhibitor, nivolumab, from the esophageal cancer cohort of the phase 2 part o…
View article: Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S3. Tumor responses as assessed by investigator using RECIST v1.1 by prior gastrectomy or liver metastasis at baseline, and by prior ICI treatment
View article: Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Fig S3. Percent change in biomarkers at C1D8 (A) and C2D8 (B), pharmacodynamic changes in plasma biomarkers from C1D1 (C), and dichotomized analysis of plasma biomarker levels and PFS (D)
View article: Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Fig S1. Patient dosing and responses over time (A) and anticancer medication received during follow-up (B)
View article: Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S1. Patient representativeness
View article: Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S5. Association of biomarkers with PFS
View article: Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Figure S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Fig S3. Percent change in biomarkers at C1D8 (A) and C2D8 (B), pharmacodynamic changes in plasma biomarkers from C1D1 (C), and dichotomized analysis of plasma biomarker levels and PFS (D)
View article: Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S4. TEAEs that occurred in >10% of patients
View article: Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S2. Previous and posttreatment anticancer therapies
View article: Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Purpose:E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in the treatment of gastric cancer. Study 120, a phase Ib/II open-label study, assessed efficacy and safety of E7…
View article: Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S2. Previous and posttreatment anticancer therapies
View article: Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S4 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S4. TEAEs that occurred in >10% of patients
View article: Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S1. Patient representativeness
View article: Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Fig S2. Absolute neutrophil counts in patients who received prophylactic pegGCSF (A) and in patients who did not receive prophylactic peg-GCSF (B), by visit
View article: Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Figure S2 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Fig S2. Absolute neutrophil counts in patients who received prophylactic pegGCSF (A) and in patients who did not receive prophylactic peg-GCSF (B), by visit
View article: Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S3 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S3. Tumor responses as assessed by investigator using RECIST v1.1 by prior gastrectomy or liver metastasis at baseline, and by prior ICI treatment
View article: Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Table S5 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Table S5. Association of biomarkers with PFS
View article: Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Supplementary Figure S1 from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Supplementary Fig S1. Patient dosing and responses over time (A) and anticancer medication received during follow-up (B)
View article: Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Data from Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Purpose:E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in the treatment of gastric cancer. Study 120, a phase Ib/II open-label study, assessed efficacy and safety of E7…
View article: Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort
Phase II Study of the Liposomal Formulation of Eribulin (E7389-LF) in Combination with Nivolumab: Results from the Gastric Cancer Cohort Open
Purpose: E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor eribulin and has shown preliminary efficacy in the treatment of gastric cancer. Study 120, a phase Ib/II open-label study, assessed efficacy and safety of E…
View article: Prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer
Prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer Open
Serum zinc levels decreased during chemotherapy in zinc-non-deficient patients at the beginning of chemotherapy and correlated with taste changes, skin rash, and itching. Therefore, investigating whether zinc supplementation ameliorates th…
View article: A prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer
A prospective observational study of zinc deficiency symptoms during first-line chemotherapy for gastric and colorectal cancer Open
Background Zinc deficiency during long-term courses of chemotherapy and its related symptoms, including skin rash, taste disorder, and oral mucositis, has not been sufficiently investigated. Methods This prospective observational study enr…
View article: WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study)
WJOG13219G: The Efficacy and Safety of FOLFOXIRI or Doublet plus Anti-VEGF Therapy in Previously Untreated BRAFV600E Mutant Metastatic Colorectal Cancer: A Multi-Institutional Registry-Based Study (BRACELET Study) Open
Triplet therapy had no survival benefit versus doublet therapy in the overall and IPTW cohorts or specific subgroups for real-world patients with BRAFV600E mutant mCRC.
View article: Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer
Association of <i>ERBB2</i> Copy Number and Gene Coalterations With Trastuzumab Efficacy and Resistance in Human Epidermal Growth Factor Receptor 2–Positive Esophagogastric and Gastric Cancer Open
PURPOSE ERBB2 copy number (CN), measured using next-generation sequencing, is a predictive biomarker for trastuzumab efficacy in human epidermal growth factor receptor 2 (HER2)–positive advanced esophagogastric and gastric cancer (AGC). We…
View article: Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer
Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer Open
Objective S-1 and modified FOLFIRINOX (mFFX) were often used as the second-line chemotherapies after failure of gemcitabine plus nab-paclitaxel (GnP) in unresectable pancreatic cancer (UPC) until nanoliposomal irinotecan plus 5-fluorouraci…
View article: Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC): FAEISS study
Primary analysis results of randomized controlled trial evaluating reactive topical corticosteroid strategies for the facial acneiform rash by EGFR inhibitors (EGFRIs) in patients (pts) with RAS wild-type (wt) metastatic colorectal cancer (mCRC): FAEISS study Open
View article: Classification of atrophic mucosal patterns on Blue LASER Imaging for endoscopic diagnosis of Helicobacter pylori-related gastritis: A retrospective, observational study
Classification of atrophic mucosal patterns on Blue LASER Imaging for endoscopic diagnosis of Helicobacter pylori-related gastritis: A retrospective, observational study Open
The Spotty pattern may represent the presence of HP infection, the Cracked pattern, a post-inflammatory change as seen after HP eradication, and the Mottled pattern, intestinal metaplasia.
View article: Retrospective Study of Surgical Gastrojejunostomy versus Gastroduodenal Stenting for Malignant Gastroduodenal Obstruction
Retrospective Study of Surgical Gastrojejunostomy versus Gastroduodenal Stenting for Malignant Gastroduodenal Obstruction Open
【目的】悪性胃十二指腸狭窄に対する胃十二指腸ステント留置術と胃空腸吻合術の成績を比較する．【方法】悪性胃十二指腸狭窄に対し当院でステント留置術を行った25例（S群）と胃空腸吻合術を行った15例（O群）について後方視的に検討した．【結果】臨床的成功率はS群対O群：84％対93％，水分摂取までの期間は0日対2日，経口摂取までの期間は1日対3日，処置後在院日数は9日対23日と全てS群で有意に短かった．入院中の医療費はS群752290円，O群1106170円と有意にS群で軽減が認め…